PHARMALAB ApS Financials, key figures and credit report
Gross profit -42.3 kDKK FY 2023 -535.3% vs 2022
EBIT -55.1 kDKK FY 2023 -1,663.4% vs 2022
Net debt 182.2 kDKK FY 2023 +62.3% vs 2022
Quick ratio 0.1 FY 2023 -0.7 vs 2022
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -28.25 | -10.27 | -17.38 | 9.71 | -42.26 |
| Total depreciation | -6.42 | -12.83 | -12.83 | ||
| EBIT | -28.25 | -10.27 | -23.79 | -3.12 | -55.09 |
| Other financial income | 0.14 | 30.98 | |||
| Other financial expenses | -0.82 | -0.06 | -0.06 | -14.01 | -8.84 |
| Pre-tax profit | -29.07 | -10.33 | -23.85 | -16.99 | -32.95 |
| Income taxes | 6.22 | 2.27 | 0.25 | 1.44 | |
| Net earnings | -22.85 | -8.05 | -23.85 | -16.74 | -31.50 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 32.08 | 19.25 | 6.42 | ||
| Tangible assets total | 32.08 | 19.25 | 6.42 | ||
| Investments total | |||||
| Long term receivables total | |||||
| Raw materials and consumables | 118.67 | 118.67 | |||
| Inventories total | 118.67 | 118.67 | |||
| Current trade debtors | 134.08 | 691.16 | |||
| Current owed by particip. interest comp. | 3.51 | ||||
| Current other receivables | 6.70 | 5.19 | 18.46 | 51.05 | |
| Current deferred tax assets | 6.22 | 4.98 | 4.98 | 5.23 | 6.67 |
| Short term receivables total | 12.92 | 13.68 | 157.52 | 747.44 | 6.67 |
| Cash and bank deposits | 18.16 | 3.44 | 6.36 | 113.89 | 33.55 |
| Cash and cash equivalents | 18.16 | 3.44 | 6.36 | 113.89 | 33.55 |
| Balance sheet total (assets) | 31.08 | 17.12 | 195.96 | 999.25 | 165.31 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 279.77 | 279.77 | 279.77 | 279.77 | 279.77 |
| Retained earnings | - 284.36 | - 307.21 | - 315.27 | - 339.12 | - 355.85 |
| Profit of the financial year | -22.85 | -8.05 | -23.85 | -16.74 | -31.50 |
| Shareholders equity total | -27.44 | -35.50 | -59.35 | -76.08 | - 107.59 |
| Non-current liabilities total | |||||
| Current trade creditors | 15.00 | 40.35 | 849.22 | 23.50 | |
| Current owed to participating | 226.11 | 215.73 | |||
| Current owed to group member | 37.62 | ||||
| Other non-interest bearing current liabilities | 20.91 | 37.62 | 214.95 | 33.67 | |
| Current liabilities total | 58.52 | 52.62 | 255.31 | 1 075.33 | 272.90 |
| Balance sheet total (liabilities) | 31.08 | 17.12 | 195.96 | 999.25 | 165.31 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated